Cost of depression: Current assessment and future directions

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 1, Issue 1, 2001, Pages 69-76

  Greenberg, Paul E ^a   Leong, Stephanie A ^a   Birnbaum, Howard G ^a  

^a Analysis Group/Economics   (United States)

Author keywords

Cost; Depression; Direct cost; Economics; Indirect cost; Workplace burden

Indexed keywords

SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ABSENTEEISM; CAREGIVER; CONTROLLED STUDY; COST OF ILLNESS; DEPRESSION; DRUG COST; ECONOMIC ASPECT; HUMAN; INCOME; MEDICAL RESEARCH; MENTAL DISEASE; MORTALITY; PREVALENCE; PRODUCTIVITY; REVIEW; UNITED STATES; WORKPLACE;

EID: 0035557285     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.1.1.69     Document Type: Review

References (66)

1. Lifetime and 12-month Prevalance of DSM-III-R Psychiatric Disorders in the United States
2. Cost of Depressive Disorders: A Review
3. Mirtazapine: A Pharmaceconomic Review of its Use in Depression
4. Cost-Effectiveness in Health and Medicine
5. Prescribing selective serotonin reuptake inhibitors for prevention of suicide
6. Selective serotonin reuptake inhibitors: Meta-analysis of efficacy and acceptability
7. Are SSRIs a cost-effective alternative to tricyclics?
8. Antidepressant pharmacotherapy: Cost comparison of SSRIs and TCAs
9. Is there an economic advantage in the use of SSRIs over TCAs in the treatment of depression?
10. The efficacy of selective serotonin reuptake inhibitors in depression: A meta-analysis of studies against tricyclic antidepressants
11. Multinational Pharmacoeconomic Evaluation of Acute Major Depressive Disorder (MDD): A Comparison of Cost-Effectiveness Between Venlafaxine, SSRIs and TCAs
12. Comparing SSRI Treatment Costs for Depression Using Retrospective Claims Data: The Role of Nonrandom Selection and Skewed Data
13. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: A multivariate analysis
14. Antidepressant pharmacotherapy: Economic evaluation of fluoxetine, paroxetine, and sertraline in a health maintenance organization
15. Course and costs of depression treatment with fluoxetine, paroxetine, and sertraline
16. Parozetine: A pharmacoeconomic evaluation of its use in depression
17. The need for an iterative process for assessing economic outcomes associated with SSRIs
18. Past-Year Use of Outpatient Services for Psychiatric Problems in the National Comorbidity Survey
19. The functioning and well-being of depressed patients: Results from the medical outcomes study
20. Adequacy and duration of antidepressant treatment in primary care
21. Depression in the community: The first pan-European study DEPRES (Depression Research in European Society)
22. What factors influence the prescribing of antidepressant pharmacotherapy? An assessment national office-based encounters
23. Trend in the Use of Antidepressant Pharmacotherapy and Diagnosis of Depression in the USA: An Assessment of Office-Based Visits 1990 to 1998
24. The national depressive and manic-depressive association consensus statement on the undertreatment of depression
25. The deliberate misdiagnosis of major depression in primary care
26. Assessing the economic impact of psychiatric disorders
27. Utilization of health and mental health services: Three epidemiological catchment area studies
28. Major Depression in Women: A Review of the Literature
29. The Economics of Women and Depression: An Employer's Perspective. Forthcoming in the
30. Major depression and all-cause mortality among white adults in the United States
31. Workplace Burden of Depression: A Case Study in Social Functioning Using Employer Claims Data
32. Treatment-Resistant Depression: Retrospective Evaluation of Economic Consequences
33. Mental Illness in the Community
34. Unrecognized depression in general practice
35. Psychiatric Comorbidity and Pharmacological Treatment Patterns Among Patients Presenting with Insomnia: An Assessment of Office-Based Encounters in the USA in 1995 and 1996
36. Effect of Declining Mental Health Service Use on Employees of a Large Corporation
37. The economic community consequences of not treating depression
38. Depressive Symptoms, Satisfaction with Health Care, and 2-Year Work Outcomes in an Employed Population
39. Depression, disability days, and days lost from work in a prospective epidemiologic survey
40. The impact of psychiatric disorders on work loss days
41. Work and earnings losses due to mental illness: Perspectives from three national surveys
42. The economic burden of depression
43. The economic impact of depression in a workplace
44. Depression in the Workplace: Effects on Short-Term Disability
45. Lost Human Capital from Early-Onset Chronic Depression
46. Earnings changes for depressed individuals treated by mental health specialists
47. Quality of life in depression: Daily life determinants and variability
48. Health-related quality of life in primary care patients with mental disorders: Results from the PRIME-MD 1000 Study
49. Suicide risk in patients with major depressive disorder
50. Effects of medical interventions on suicidal behavior
51. The economic burden of suicide in the United States in the Year 2000
52. Caring for Depression
53. The enhancement of social functioning as a therapeutic principle in the management of depression
54. The Social Consequences of Psychiatric Disorders, III: Probability of Marital Stability
55. Social Consequences of Psychiatric Disorders, II: Teenage Parenthood
56. Social Consequences of Psychiatric Disorders, I: Educational Attainment
57. Expenditures for the Treatment of Major Depression
58. The Workplace Burden of Depression: Underlying Causes, Recent Empirical Findings, and Future Directions
59. Absenteeism Among Employees Treated for Depression
60. Management of Major Depression in the Workplace: Impact on Employee Work Loss
61. Depression and Work Productivity: The Comparative Costs of Treatment Versus Nontreatment
62. The Economic Burden of Depression in 1990
63. Depression in the workplace: An economic perspective
64. The economic burden of affective disorders
65. "Economic Analysis of Patients with Attention Deficit Hyperactivity Disorder"
66. The role of health risk factors and disease on worker productivity